AveXis Inc.

2275 Half Day Road
Suite 200
United States

Tel: 844-4-AVEXIS

Show articles for this employer

About AveXis Inc.

AveXis, a Novartis company, is the world’s leading gene therapy company, redefining the possibilities for patients and families affected by life-threatening genetic diseases through our innovative gene therapy platform. Founded in 2013 and headquartered in Bannockburn, IL, the goal of AveXis’ cutting-edge science is to address the underlying, genetic root cause of diseases. AveXis pioneered foundational research, establishing AAV9 as an ideal vector for gene transfer in diseases affecting the central nervous system, laying the groundwork to build a best-in-class, transformational gene therapy pipeline. AveXis received its first U.S. Food and Drug Administration approval in May 2019 for the treatment of spinal muscular atrophy (SMA). AveXis is also developing therapies for other genetic diseases, including Rett syndrome and a genetic form of amyotrophic lateral sclerosis (ALS) SOD1. Be a part of a team reimagining the treatment of rare and devastating genetic diseases with transformational gene therapies.

Ownership: Public

Stock Symbol: NVS

Stock Exchange: NYSE

Facebook  Twitter  LinkedIn

176 jobs with AveXis Inc.